Candida albicans: the current status regarding vaginal infections
Applied Microbiology and Biotechnology · 10.04.2025 · 109 (1)
DOI: 10.1007/s00253-025-13478-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 10.04.2025. Verfasst von Margarida Faustino und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biorbis Unipessoal Lda, Rua Diogo Botelho 1327, 4169 - 005, Porto, Portugal. afaustino@ucp.pt. Hauptthemen laut MEDLINE: Candida albicans, Candidiasis, Vulvovaginal. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, Universidade Católica Portuguesa.
Abstract (Originalsprache)
Vaginal infections caused by Candida albicans are a significant global health concern due to their recurrence and negative impact on quality of life. This review examines the pathogenesis of C. albicans infections, emphasizing critical virulence factors such as biofilm formation, adherence, and phenotypic switching. Risk factors include immune system suppression, antibiotic use, and hormonal changes, all of which can lead to fungal overgrowth and infection. Current prevention and/or treatment strategies primarily rely on antifungal therapies, personal hygiene practices, and probiotics. However, challenges like antifungal resistance, recurrence, and limited treatment efficacy highlight the need for innovative approaches. Therefore, emerging methods such as novel antifungal agents, vaccines, and nanotechnology-based delivery systems offer promising advancements to improve infection control. Additionally, the immune system plays a key role in preventing C. albicans infections, with both innate and adaptive immunity acting to restrict fungal colonization and growth. Commercially available products, such as antifungal creams, vaginal probiotics, and hygiene solutions, are practical options but often lack long-term efficacy. Persistent challenges, including resistance, patient noncompliance, and restricted access to emerging therapies, hinder comprehensive prevention and treatment efforts. Thus, future research should focus on promoting interdisciplinary approaches, integrating personalized medicine, and enhancing healthcare accessibility. This review intends to present the current state of the art within the abovementioned issues and to enhance the understanding of the multifactorial nature of C. albicans infections and advanced prevention strategies, which are essential to reduce the burden of vaginal candidiasis worldwide and improve patient quality of life outcomes. Key points • Candida albicans pathogenesis involves biofilms, adherence, and phenotypic switching. • Vaccines, nanotechnology, and new drugs offer improved prevention and treatment. • Addressing antifungal resistance and patient compliance is key for prevention success. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biorbis Unipessoal Lda, Rua Diogo Botelho 1327, 4169 - 005, Porto, Portugal. afaustino@ucp.pt.
- Universidade Católica Portuguesa, CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Rua Diogo Botelho 1327, 4169 - 005, Porto, Portugal. afaustino@ucp.pt.
- Biorbis Unipessoal Lda, Rua Diogo Botelho 1327, 4169 - 005, Porto, Portugal.
- Universidade Católica Portuguesa, CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Rua Diogo Botelho 1327, 4169 - 005, Porto, Portugal.
- CBMA (Center of Molecular and Enviromental Biology), Department of Biology, Universidade do Minho, Campus Gualtar, 4710 - 057, Braga, Portugal.
- IB-S (Institute of Science and Innovation for Bio-Sustainability), Campus de Gualtar, Universidade do Minho, 4710 - 057, Braga, Portugal.
Förderung
- Fundação para a Ciência e a Tecnologia
- Universidade Católica Portuguesa
Zitieren
APA
Faustino, M., Ferreira, C. M. H., Pereira, A. M., & Carvalho, A. P. (2025). Candida albicans: the current status regarding vaginal infections. Applied Microbiology and Biotechnology, 109(1). https://doi.org/10.1007/s00253-025-13478-2
Vancouver
Faustino M, Ferreira CMH, Pereira AM, Carvalho AP. Candida albicans: the current status regarding vaginal infections. Applied Microbiology and Biotechnology. 2025;109(1). doi:10.1007/s00253-025-13478-2
BibTeX
@article{Faustino2025,
author = {Faustino, Margarida and Ferreira, Carlos M H and Pereira, Ana Margarida and Carvalho, Ana P},
title = {Candida albicans: the current status regarding vaginal infections},
journal = {Applied Microbiology and Biotechnology},
year = {2025},
volume = {109},
number = {1},
doi = {10.1007/s00253-025-13478-2}
}
EUVIMED